Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody
Trinomab Biotechnology Co., Ltd. (SHA: 688806) officially listed on the Science and Technology Innovation Board...
IPO
Immvira Bioscience Files for Hong Kong IPO to Advance Novel Oncolytic Immunotherapy and Engineered Exosome Pipeline
Immvira Bioscience Inc., a clinical-stage biotechnology company founded in 2015, has filed its prospectus for...
Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset
Braveheart Bio, a Delaware-based biopharmaceutical company founded in 2024, submitted its IPO prospectus to the...
Fosun Pharmaceutical Approves Hong Kong IPO Spin-Off of Vaccine Subsidiary Fosun Adgenvax
Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced today that its board of...
CSPC Innovation Pharmaceutical Files Hong Kong IPO Prospectus Following Strategic Evolution from Caffeine Producer to Biopharmaceutical Player
CSPC Innovation Pharmaceutical Co., Ltd., a subsidiary of CSPC Pharmaceutical Group (HKG: 1093), has released...
Zhiyi Biotechnology Files Hong Kong IPO Prospectus as China’s Leading Live Biotherapeutic Products Developer
Guangzhou Zhiyi Biotechnology Co., Ltd. announced the release of its initial public offering (IPO) prospectus...
Alebund Pharmaceuticals Raises $163M in Hong Kong IPO to Advance Kidney Disease Pipeline
Alebund Pharmaceuticals (Jiangsu) Limited (HKG: 9637) successfully completed its initial public offering (IPO) on the...
Shanghai Juncell Therapeutics Files for HKEX Listing with Breakthrough TIL Therapy GC101 for Solid Tumors
Shanghai Juncell Therapeutics Co., Ltd. announced it has published its prospectus and filed for listing...
Lynk Pharmaceuticals Files for Hong Kong IPO – Autoimmune Pipeline Led by JAK Inhibitors and Novel Protein Degraders
Lynk Pharmaceuticals Co., Ltd. announced it has published its prospectus and formally applied for listing...
TriApex Laboratories Files for Hong Kong IPO – Next-Generation CRO with 240+ NMPA Approvals
TriApex Laboratories Co., Ltd. announced it has published its prospectus and formally applied for listing...
Ningbo Sanxing Medical Electric Files HKEX Prospectus with Dual Business Model in Power Equipment and Rehabilitation Services
Ningbo Sanxing Medical Electric Co., Ltd. announced it has filed its prospectus for listing on...
Lannacheng Biotechnology Files HKEX Prospectus with 13-Candidate Radiopharmaceutical Pipeline
Yantai Lannacheng Biotechnology Co., Ltd. announced it has filed its prospectus for listing on the...
Micot Pharmaceutical Successfully Lists on Hong Kong Stock Exchange with HK$1.22 Billion IPO
Shaanxi Micot Pharmaceutical Technology Co., Ltd. (HKG: 2355) announced its successful listing on the Hong...
HJ Science Launches HK$1.11 Billion IPO on Hong Kong Exchange to Advance Clinical-Stage Pipeline in Autoimmune, Metabolic, and Oncology Therapies
HJ Science Co., Ltd., (HKG: 6132) a China-based clinical-stage biotechnology company, announced its proposed initial...
Hangzhou Highlightll Pharmaceutical Files for Hong Kong IPO with Seven-Candidate Pipeline Targeting Autoimmune and Neurodegenerative Diseases
Hangzhou Highlightll Pharmaceutical Co., Ltd., a clinical-stage biopharmaceutical company founded in 2017, has filed a...
True Health Medical Files Hong Kong IPO for Percutaneous Surgery Robot Portfolio with Multiple China-First Innovations
Guangdong True Health Medical Technology Development Co., Ltd., a leading Chinese developer of percutaneous puncture...
LongBio Pharma Raises HKD 1.25 Billion in Hong Kong IPO – Clinical-Stage Biotech Advances Anti-IgE and Bifunctional Complement Inhibitors for Allergic and Autoimmune Diseases
LongBio Pharma, a China-based clinical-stage biopharmaceutical company focused on biomacromolecule therapeutics for allergic and autoimmune...
Shanghai Simpletouch Robot Files for Hong Kong IPO – Advancing Percutaneous Puncture Surgical Robotics Platform
Shanghai Simpletouch Robot Co., Ltd. has filed its prospectus with the Hong Kong Stock Exchange...
Sinocelltech Files for Hong Kong Secondary Listing to Expand Global Capital Access and Therapeutic Portfolio
Sinocelltech Group Ltd (SHA: 688520) has filed its prospectus with the Hong Kong Stock Exchange,...
Shimai Pharmaceutical Files Hong Kong IPO Prospectus with Advanced T-Cell Engager Pipeline
Zhejiang Shimai Pharmaceutical Co., Ltd., a T-cell engager (TCE) specialist founded in 2017, has filed...